» Articles » PMID: 32414852

Multiple Myeloma with Central Nervous System Relapse

Overview
Journal Haematologica
Specialty Hematology
Date 2020 May 17
PMID 32414852
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Central nervous system involvement in multiple myeloma is a rare complication but carries a very poor prognosis. We provide a review of current literature, including presentation, treatment and survival data, and describe our experience in a regional hematologic malignancy diagnosis center where, over a 15-year period, ten cases were identified. Although the median age of onset, frequently between 50-60 years, is comparatively young, those diagnosed usually have a preceding diagnosis of multiple myeloma and often have had several lines of treatment. We discuss putative underlying factors such as prior treatment and associations including possible risk factors and features suggestive of a distinct biology. Central nervous system involvement may be challenging to diagnose in myeloma, displaying heterogeneous symptoms that can be confounded by neurological symptoms caused by the typical features of myeloma or treatment side-effects. We discuss the clinical features, imaging and laboratory methods used in diagnosis, and highlight the importance of considering this rare complication when neurological symptoms occur at presentation or, more commonly, during the disease pathway. In the absence of clinical trial data to inform an evidence-based approach to treatment, we discuss current and novel treatment options. Finally, we propose the establishment of an International Registry of such cases as the best way to collect and subsequently disseminate presentation, diagnostic and treatment outcome data on this rare complication of multiple myeloma.

Citing Articles

Plasma Cells Out for a Swim! A Study on Myelomatous Involvement of Effusion Fluid and Cerebrospinal Fluid: A 10-Year Experience from a Tertiary Cancer Center.

De S, Samanta S, Shah M J Cytol. 2025; 42(1):48-53.

PMID: 40078346 PMC: 11896116. DOI: 10.4103/joc.joc_87_24.


Visual impairment as the initial presentation in multiple myeloma: a case report and literature review.

Xu Z, Yang S, Zhu L, Wan X, Xu H, Chen H Transl Cancer Res. 2024; 13(9):5149-5156.

PMID: 39430820 PMC: 11483438. DOI: 10.21037/tcr-24-511.


Isolated central nervous system (CNS) relapse of multiple myeloma 11 years after autologous stem cell transplantation: a case report.

Reynoso-Gomez E, Quintero-Hernandez C AME Case Rep. 2024; 8:111.

PMID: 39380867 PMC: 11459409. DOI: 10.21037/acr-24-19.


Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment.

Verbruggen S, Freeman C, Freeman F Cancers (Basel). 2024; 16(5).

PMID: 38473251 PMC: 10931336. DOI: 10.3390/cancers16050889.


Isolated Progression of Multiple Myeloma into the Extramedullary Plasmacytoma of Dura Mater: A Case Report and Review of the Literature.

Tyczynska A, Turski M, Zarzycka E, Zaucha J Biomedicines. 2023; 11(4).

PMID: 37189843 PMC: 10135956. DOI: 10.3390/biomedicines11041225.


References
1.
Campo E, Cymbalista F, Ghia P, Jager U, Pospisilova S, Rosenquist R . aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018; 103(12):1956-1968. PMC: 6269313. DOI: 10.3324/haematol.2018.187583. View

2.
Kauffmann G, Buerki R, Lukas R, Gondi V, Chmura S . Case Report of Bone Marrow-Sparing Proton Therapy Craniospinal Irradiation for Central Nervous System Myelomatosis. Cureus. 2018; 9(11):e1885. PMC: 5786350. DOI: 10.7759/cureus.1885. View

3.
Dimopoulos M, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M . Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018; 379(19):1811-1822. DOI: 10.1056/NEJMoa1805762. View

4.
Gozzetti A, Cerase A, Bocchia M . Central nervous system multiple myeloma. Ann Hematol. 2016; 95(3):519-20. DOI: 10.1007/s00277-015-2586-6. View

5.
Chang H, Sloan S, Li D, Stewart A . Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004; 127(3):280-4. DOI: 10.1111/j.1365-2141.2004.05199.x. View